Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115830 · ClinicalTrials.gov registry record · Phase 3
Rho Kinase in Patients With Atherosclerosis
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00115830 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00115830, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs commonly prescribed by doctors to lower cholesterol, on certain functions of platelets (cells that cause blood clots), white blood cells (cells that are responsible for inflammation), and blood flow regulation by arteries. This is important because we are looking at ways to more effectively prevent atherosclerosis (plaque buildup in blood vessels) and heart disease. Many studies have demonstrated that these drugs are effective at reducing inflammation and stabilizing plaques. We are interested in better understanding the effects of these medicines on inflammation (pain and swelling) and the mechanism by which they act. Hypothesis: Atorvastatin (40mg) will reduce inflammatory markers and activity more than Rosuvastatin (10mg) in spite of equal LDL-C reduction.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115830
The ClinicalTrials.gov registry entry for NCT00115830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT00115830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115830 about?
NCT00115830 is a clinical study titled "Rho Kinase in Patients With Atherosclerosis". The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs commonly prescribed by doctors to lower cholesterol, on certain functions of platelets (cells that cause blood clots), white bl...
What is the current status of trial NCT00115830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2004-12. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00115830?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00115830?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.